
EV two-wheeler sales soared 34x in 4 years, but market share stuck at 4%: Study
New Delhi: Electric vehicle (EV) sales in India have grown rapidly across segments in the last decade, but adoption rates remain modest despite significant fiscal support, a new study by the Institute for Energy Economics and Financial Analysis (IEEFA) has found. The report, From Incentives to Adoption, presents a 10-year review (2014–2023) of government subsidies and policy interventions under FAME-I, FAME-II, Production Linked Incentives (PLI), and state schemes, and assesses their effectiveness across five EV segments.
In the electric two-wheeler (E2W) segment, sales jumped from 19,333 units in FY2019 to over 6.5 lakh units in FY2023. However, the adoption rate – the share of electric vehicles in overall two-wheeler sales – was only 4% by the end of 2023. 'FAME-II's higher subsidy intensity (28.65%) compared to FAME-I (14.32%) boosted absolute E2W sales by up to 9 times, but had limited impact on the overall market composition,' the report states.
According to Charith Konda, Energy Specialist at IEEFA and one of the co-authors, 'The government should continue offering purchase subsidies to sustain momentum but clearly communicate a phased-down trajectory for the longer term.'
In the electric three-wheeler passenger (E3WP) segment, early policy support under FAME-I drove a 10x market multiplier effect. Around 27,000 additional vehicles were directly attributed to subsidies under FAME-I, with total sales reaching 2.67 lakh units by March 2019. The segment, however, matured during the FAME-II period and showed limited incremental impact from later subsidies.
The electric three-wheeler cargo (E3WC) category saw a market share rise from 0.03% in 2015 to over 31% by 2023. The study found this growth was largely driven by operating cost advantages rather than central subsidies. A 1% reduction in operating cost led to a 0.563% increase in sales, highlighting the role of business economics in commercial segments.
In the electric four-wheeler commercial (E4WC) category, sales improved after FAME-II and PLI schemes were implemented. A one-standard-deviation increase in subsidy intensity led to a 5% rise in sales. However, the adoption rate was still less than 1%. States that implemented incentives saw 211% higher sales growth than those that did not.
For electric four-wheelers in the private segment (E4WP), sales grew due to new model launches and consumer demand, but adoption rates remained below 2%. The report highlights the need for continuing support in this segment.
The report found that both FAME-I and FAME-II failed to make a statistically significant impact on electric bus (e-bus) adoption. Only 4,766 units were subsidised against a target of 7,262, and the sector continues to face structural barriers such as limited financing access and high upfront costs.
'Coordinated central and state action, pairing targeted purchase incentives, infrastructure rollout, and manufacturing scale-up can help electric cars compete effectively with their counterparts in India's commercial vehicle market,' said Saurabh Trivedi, Sustainable Finance Specialist at IEEFA.
The study recommends continued fiscal support, investment in public charging infrastructure, interest rate subvention for buses, and targeted financing support for smaller commercial operators.
'As India transitions from FAME schemes to PM E-DRIVE and other similar initiatives, policymakers must recognise that each EV segment requires tailored intervention,' Konda added.
The report draws on panel data of 21,526 observations over 10 years, offering a first-of-its-kind empirical assessment of India's EV subsidy performance using econometric techniques such as difference-in-differences and synthetic control methods.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Indian Express
2 hours ago
- Indian Express
Google Gemini now supports scheduled actions, introduces new swipe gesture for Live
Google was one of the few companies that jumped on the AI bandwagon early on, but the tech giant still seems to be playing catch-up with startups like OpenAI. Earlier this year, in January, the Sam Altman-led company introduced a new feature that enabled users to schedule tasks in ChatGPT to run automated prompts. Now, in a blog post, Google has announced that it is bringing 'Scheduled Actions' to Gemini. Announced at this year's I/O, Google says the new functionality is 'designed to proactively handle your tasks.' Similar to ChatGPT's schedule tasks, Gemini users will now be able to streamline their routine tasks and even get personalised updates from the AI chatbot. The tech giant says users can now ask Gemini to do things like completing a task at a specified time, or changing the prompt you are already using for a recurring task. Moreover, Gemini can now show you a summary of your calendar, unread emails, and fetch information and give updates about your favourite sports team on the go. However, the scheduled actions feature is limited to users with a Google AI Pro or Ultra subscription and eligible Google Workspace business and education plans. Also, it is still unclear if Gemini, like ChatGPT, has limited scheduled action to ten active tasks and if they can pause or delete an old task if they hit the limit. Google also said that Gemini will soon get an 'upgraded preview' of Gemini 2.5 Pro. The new large language model builds on the company's recently unveiled 2.5 Pro model, which is better than its predecessors in coding. The company is also making it easier for users to access Gemini Live. Instead of tapping on the dedicated Gemini Live action from the bottom of the screen, you can now simply swipe from the right side of the screen to the left to open Gemini Live.


Hindustan Times
7 hours ago
- Hindustan Times
Delhi's 3rd Ring Road to open by August
The six-lane Urban Extension Road-2 (UER-2), planned as Delhi's third Ring Road, is set to open by August, effectively cutting travel time from Indira Gandhi International (IGI) Airport to parts of south-west and north-west Delhi — and the Haryana border — by 40–60%, officials aware of the project have said. Over 95% of the construction is complete, with sections passing through Najafgarh, Mundka and Alipur already operational. The National Highways Authority of India (NHAI), which is implementing the project, presented its progress status during a recent meeting between Union transport minister Nitin Gadkari and Delhi chief minister Rekha Gupta and her cabinet colleagues. According to officials, Delhi-NCR is currently seeing road infrastructure projects worth ₹34,589 crore underway across 594km, while another ₹23,850 crore has been earmarked for 128km of roadworks that are about to begin. Originally conceived under the Delhi Master Plan Road 2021, UER-2 was later notified as a national highway to be readied in five construction packages. Spanning 76km — of which 54.21km lies in Delhi and 21.5km in Haryana — the ₹8,000 crore corridor is being funded by the Delhi Development Authority (DDA) for its Delhi section and built by NHAI. 'The UER-2 will offer faster connectivity between Chandigarh, Gurugram and IGI Airport. It has also opened up access to previously underserved parts of Delhi such as Najafgarh, Mundka, Karala, Alipur, and Bawana, enhancing links to south Delhi, Noida, Faridabad, and major highways like NH-48,' a report from the Union road ministry, shared with the Delhi government, noted. During the Lok Sabha campaign in January, Gadkari had highlighted the reuse of two million tonnes of legacy waste from Ghazipur landfill in UER-2's construction — a move that reduced the height of the landfill's trash mountain by seven metres. In a related development, the underpass stretch of the Dwarka Expressway near IGI Airport — which connects with UER-2 — is nearing completion and expected to open in the next 15 days. The expressway will serve as a bypass to NH-48 and improve access between the airport, UER-2, Dwarka and Gurugram. It will also offer a direct link to Yashobhoomi in Sector 25, Dwarka. 'The Dwarka Expressway has significantly eased travel from parts of Delhi such as Mahipalpur, Dwarka, Vasant Kunj and Najafgarh to Gurugram and IGI Airport. The Haryana section was opened in March 2024, while the Delhi stretch, which includes a tunnel and underpasses, is likely to be operational by mid-June,' an official said. The 28-km-long Dwarka Expressway, built at a cost of ₹8,611 crore, is now 98% complete. Officials added that NHAI is increasingly using inert material recovered from legacy waste through biomining for road construction — including projects like the DND–Faridabad–Ballabhgarh–Sohna bypass and UER-II. The use of silt, stones, and construction debris is aimed at cutting landfill volume, conserving natural resources, lowering construction costs and reducing emissions. The 28-km-long expressway, built at a cost of ₹8,611 crore, is now 98% complete. Officials added that NHAI is increasingly using inert material recovered from legacy waste through biomining for road construction — including projects like the DND–Faridabad–Ballabhgarh–Sohna bypass and UER-II. The use of silt, stones, and construction debris is aimed at cutting landfill volume, conserving natural resources, lowering construction costs and reducing emissions.


Business Standard
16 hours ago
- Business Standard
G.C Chemie Pharmie: Four Decades of Innovation and Trust in Pharmaceuticals and Nutraceuticals
India PR Distribution Mumbai (Maharashtra) [India], June 6: G.C Chemie Pharmie Pvt. Ltd. (GCCPL), a pioneer in India's pharmaceutical, nutraceutical, functional foods, and biopharmaceutical sectors, proudly celebrates over 44 years of innovation and service excellence. Founded in 1981 by visionary entrepreneur Gautam Shah, GCCPL has evolved into a globally connected and innovation-driven enterprise known for its commitment to trust, transparency, and quality. What began as an API trading and distribution firm has transformed into a diversified pharmaceutical powerhouse. GCCPL's impressive timeline of achievements includes: - 2009/2010: Acquisition of Eagle Chemical Works, establishing its own API manufacturing capabilities - 2009: Release of its first vaccine, marking a significant milestone in biopharmaceuticals - 2010/2011: Launch of its P2P division, introducing affordable medicines to the Indian market -2018: Entry into the sports nutrition space - 2022: Creation of a preventive healthcare division with a focus on gynecology and orthopedics - 2023: Establishment of a dedicated vaccine division to expand immunization solutions Driven by a mission to lead through innovative thinking and technology adoption, GCCPL delivers tailored solutions across pharmaceutical, nutraceutical, and functional food categories. The company continues to differentiate itself through its strong regulatory acumen, cutting-edge R & D, and a global network of manufacturing and distribution partners. "At GCCPL, innovation is not a buzzword--it's the foundation of our growth strategy," said Founder and Chairman Gautam Shah. "We're proud to be one of India's few private companies to bring the pneumococcal vaccine to the domestic market, second only to Pfizer." Recent product highlights include UC-II®, a patented undenatured type II collagen supplement, and Pylopass™, a breakthrough strain-based probiotic--both showcasing GCCPL's commitment to introducing clinically backed, innovative health solutions to India. With a sterling reputation for regulatory compliance, deep market research, and financial integrity--as affirmed by CRISIL's highest rating A2+ GCCPL stands as a trusted partner for businesses and healthcare providers seeking reliable, next-generation healthcare products. About G.C Chemie Pharmie Pvt. Ltd. Founded in 1981, GCCPL is an Indian-based pharmaceutical and nutraceutical company with a global footprint. Known for its reliability, innovation, and commitment to quality, GCCPL offers customized, technology-driven healthcare solutions to meet the evolving needs of today's market. The company maintains a strong presence in vaccines, preventive care, functional foods, and advanced supplements.